Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep enables CAR-T trafficking in solid tumors

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 28, 2024 12:22pm

178 Views

Post# 35958240

RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumors

A recently published paper in the New England Journal of Medicine dated February 21, 2024, found that CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious in three different autoimmune diseases, systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis.

https://www.nejm.org/doi/full/10.1056/NEJMoa2308917

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec